Improving Patient Access To Biosimilar Drugs: Two Key Barriers

Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, … Continue reading

Marketing Off-label Use of Drugs: A Path Much Abused?

As many would know, prescribing any medicine for disease conditions that are not approved by the drug approving authorities while granting its marketing approval, is generally termed as ‘off-label’ use of drugs. It is also a usual practice in most … Continue reading

Path-breaking medicines are just not enough… a comprehensive healthcare reform in India is long overdue

The Prime Minister of India, Dr. Manmohan Singh reiterated the following in his speech at the 30th Convocation of PGIMER, Chandigarh on November 3, 2009: ”As in economics, so as in medicine too, it is easy to get lost in … Continue reading

Witty promise – is it path breaking?

The Guardian, Saturday 14 February, 2009 reported that Andrew Witty, the head honcho of GlaxoSmithKline (GSK) strongly believes, “patents are social construct that must rest upon ethical foundation”.Witty with his earlier various ‘out of box’ decisions, appears to gradually establish … Continue reading